Evercyte bringing EV toolbox insights to GSEV/ASEV Autumn Meeting
Press Release | Evercyte GmbH
NOVEMBER 14, 2019
Evercyte will be a leading sponsor of the event and will also be an exhibitor with a stand at Booth 5 at the Technical University of Munich (TUM) Freising-Weihenstephan, showcasing its expanding portfolio of services and products for customer-tailored cell line development of human cell lines and gene editing, with particular focus on its capabilities in EV engineering.
Developing the EV toolbox
These include generating specific targeted EVs and recombinant EVs, EV characterization and production, identifying novel hosts for EVs and generating customer tailored human telomerized cells customized by cell type, donor and gene editing for EV production.
Together, these form an extensive toolbox for EV applications that Evercyte CSO Dr. Johannes Grillari, will detail in his presentation to the meeting “From cellular senescence to an EV toolbox: a journey”, which will be one of the four Gold Sponsor talks that round out the second morning of the meeting (Friday, November 29, 1130-1230).
Key roles for human stem cell EVs
“I hope to show how EV-based research has become an integrated process that plays an ever more important role in regenerative and transplant medicine and anti-tumor therapy as well as immunotherapy,” said Johannes Grillari.
“Crucially we have discovered that EVs secreted from human stem cells seem to be just as effective as the transplanted cells in various disease models,” he added.
The Evercyte stand team will be led by Regina Weinmüllner and Claudia Lindner while Evercyte CTO Dr. Regina Grillari will also be present at the conference.
Evercyte GmbH, based in Vienna, manufactures a range of innovative cell-based products; human relevant and standardizable cell models for pre-clinical testings, induced pluripotent stem cells and telomerized cells, with fully documented history and high quality for production of extracellular vesicles for clinical applications, in vitro bioassays including potency assays for extracellular vesicles.
Evercyte has also become a key player in the development of induced pluripotent stem (iPS) cells from human urine as a non-invasive source for generating cell material. The company also offers a range of cell-based assays, used in development of drug screening strategies and other applications. It also develops assays to individual specification to help customers reduce their time and spend on drug discovery and development.
Founded in 2011, the Vienna-based company successfully offers tools and the know-how necessary for the establishment of standardized high-throughput target identification and drug screening strategies, for toxicity studies, or for efficacy testing from statistically relevant numbers of donors. In addition, Evercyte now also focuses on using telomerized cells as cell factories. Further information at http://www.evercyte.com.
About GSEV/ASEV Autumn Meeting 2019
The German Society for Extracellular Vesicles (GSEV) staged its first Autumn Meeting in partnership with the Austrian Society for Extracellular Vesicles (ASEV) in 2018. The joint meeting provides a forum for young researchers specializing in extracellular vesicle studies to share their knowledge.
The 2nd GSEV/ASEV Autumn Meeting, will provide a platform for numerous oral and poster presentations from young scientists and PhD students.
The meeting will focus on a range of topics including methodological improvements in isolating pure EVs, correct characterization, new and early EV biomarkers, new therapeutic applications and EVs in human and animal physiology.
The Autumn Meeting is a two-day event opening November 28 at the Technical University of Munich’s Weihenstephan Science Center for Nutrition.
Further information at: https://www.extracellular-vesicles.de/gsev-meetings/.
Elisabeth Semmelrock, Project Management & Business Development, Evercyte GmbH
Tel: +43 699 107 094 01
Click on Evercyte at GSEV 2019 for other information.
Click on Evercyte to contact the company directly.
Click on EV Research Focus to learn more about Evercyte’s work in extracellular vesicles.
Click on Evercyte portfolio to download current product catalogue.